US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SIMPLIFY MANAGED FUTURES STRATEGY ETF

29.77

+0.17000.57%

Post-market: 29.71-0.0598-0.20%16:25 EDT

Volume:521.16K

Turnover:15.48M

Market Cap:- -

PE:- -

High:29.78

Open:29.64

Low:29.61

Close:29.60

Loading ...

Overview Company News Filings

Are managed futures ETFs nearing a Europe comeback?

Millions of Americans Have Failed to Comply With New Tax Ownership Rules -- Barrons.com

DIC to Unveil Omnidirectional Multicopter HAGAMOSphere™, Named as CES Innovation Awards® 2025 Honoree, at CES 2025

Garmin Unified Cabin automotive OEM solution named 2025 CES Innovation Award Honoree

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

Man Group's trend tracking fund is having one of its worst years ever

Hydrific Named as CES Innovation Awards 2025 Honoree

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

PHAXIAM Reports Third-Quarter 2024 Financial Information

Press Release: Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Voyager Reports Third Quarter 2024 Financial and Operating Results

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CTA/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CTA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","market":"US","secType":"STK","nameCN":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","latestPrice":29.77,"timestamp":1743537600000,"preClose":29.6,"halted":0,"volume":521162,"hourTrading":{"tag":"盘后","latestPrice":29.7102,"preClose":29.77,"latestTime":"16:25 EDT","volume":142,"amount":4219.566068,"timestamp":1743539129751},"delay":0,"floatShares":32275001,"shares":0,"eps":0,"marketStatus":"Post-Market Trading","change":0.17,"latestTime":"04-01 17:17:32 EDT","open":29.64,"high":29.78,"low":29.6101,"amount":15480138.309716,"amplitude":0.00574,"askPrice":32.46,"askSize":100,"bidPrice":27.17,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1743552000000},"marketStatusCode":4,"adr":0,"exchange":"AMEX","adjPreClose":29.6,"sharesOutstanding":32275001,"nav":29.43,"aum":949965765.66,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":29.69,"preClose":29.6,"latestTime":"09:27 EDT","volume":389,"amount":11597.180366999999,"timestamp":1743514030646},"postHourTrading":{"tag":"盘后","latestPrice":29.7102,"preClose":29.77,"latestTime":"16:25 EDT","volume":142,"amount":4219.566068,"timestamp":1743539129751},"volumeRatio":1.093655,"impliedVol":0.0916,"impliedVolPercentile":0.4118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CTA\",,,,,undefined,":{"symbol":"CTA","floatShares":32275001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.093655,"shares":0,"dividePrice":1.1919,"high":29.78,"amplitude":0.00574,"preClose":29.6,"low":29.6101,"week52Low":25,"pbRate":"--","week52High":30.213,"institutionHeld":0,"latestPrice":29.77,"eps":0,"divideRate":0.040037,"volume":521162,"delay":0,"ttmEps":0,"open":29.64,"prevYearClose":27.89,"prevWeekClose":29.43,"prevMonthClose":29.6,"prevQuarterClose":29.6,"fiveDayClose":29.49,"twentyDayClose":29.05,"sixtyDayClose":27.98},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CTA\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2489541431","title":"Are managed futures ETFs nearing a Europe comeback?","url":"https://stock-news.laohu8.com/highlight/detail?id=2489541431","media":"ETF stream","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489541431?lang=en_us&edition=fundamental","pubTime":"2024-12-05 18:45","pubTimestamp":1733395500,"startTime":"0","endTime":"0","summary":"Managed futures ETFs have tried – and failed – to gain traction in Europe before, but the market might now be ready for another shot.In a managed futures strategy, a Commodity Trading Advisor (CTA) us","market":"us","thumbnail":"//images.ctfassets.net/lr0atmu04u9z/7imy04VoG9hwr1VQwRDaOY/0798f187a63e7a9e7c8aa7532b4655dd/shutterstock_1050436808.jpg","type":0,"news_type":0,"thumbnails":["//images.ctfassets.net/lr0atmu04u9z/7imy04VoG9hwr1VQwRDaOY/0798f187a63e7a9e7c8aa7532b4655dd/shutterstock_1050436808.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.etfstream.com/articles/are-managed-futures-etfs-nearing-a-europe-comeback","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"etfstream_highlight","symbols":["FDN","BK4550","BK4585","BK4588","CTA"],"gpt_icon":0},{"id":"2488659142","title":"Millions of Americans Have Failed to Comply With New Tax Ownership Rules -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2488659142","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488659142?lang=en_us&edition=fundamental","pubTime":"2024-12-01 17:00","pubTimestamp":1733043600,"startTime":"0","endTime":"0","summary":"Whether you are an owner of a large private business with cross-border operations or a simple LLC holding a family cottage, it's likely that you are obligated to comply with new federal ownership disclosure rules by year-end -- but have failed to do so.Three-quarters of the 32 million private companies and pass-through entities that are required to file ownership information to the U.S. Department of Treasury's Financial Crimes Enforcement Network  starting this year still haven't done so, risking up to a $10,000 penalty or jail time for noncompliance.The new rules, passed under the Corporate Transparency Act  in 2021, apply to people who have substantial control or at least a 25% stake in a business or pass-through entity that isn't registered with a federal government agency such as the Securities and Exchange Commission.This generally includes LLCs and private corporations such as S corporations and businesses that were created by filing documents with a state government, and foreig","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2485772484","title":"DIC to Unveil Omnidirectional Multicopter HAGAMOSphere™, Named as CES Innovation Awards® 2025 Honoree, at CES 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2485772484","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485772484?lang=en_us&edition=fundamental","pubTime":"2024-11-22 10:00","pubTimestamp":1732240800,"startTime":"0","endTime":"0","summary":"DIC's omnidirectional architecture multirotor, HAGAMOSphere is the drone that can move forward, backward, left, and right without tilting the aircraft because eight propellers are mounted diagonally on a cubic frame. . DIC is a global fine chemical manufacturer with a diverse portfolio of products, including printing inks, pigments, and synthetic resins. Its management vision is \"We improve the human condition by safely delivering color and comfort for sustainable prosperity －Color & Comfort－,\" which seeks to provide color and comfort to society while working to solve social issues and provide new value to society.Under the concept of \"Direct to Society,\" DIC aims to propose new values to society beyond the framework of conventional chemical manufacturers and creating diverse businesses across industries in an ecosystem. At CES 2025, DIC will introduce \"HAGAMOSphere,\" its concept model, to capture various social needs and utilize it for future business creation.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7S4XL_W6nn2ATC4avOEOCw--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/26faefc43a683a20a74e640fb4ddfa69","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7S4XL_W6nn2ATC4avOEOCw--~B/aD0zMjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/26faefc43a683a20a74e640fb4ddfa69"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dic-unveil-omnidirectional-multicopter-hagamosphere-020000962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTA","DICCF","BK4109"],"gpt_icon":0},{"id":"2485816467","title":"Garmin Unified Cabin automotive OEM solution named 2025 CES Innovation Award Honoree","url":"https://stock-news.laohu8.com/highlight/detail?id=2485816467","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485816467?lang=en_us&edition=fundamental","pubTime":"2024-11-21 19:59","pubTimestamp":1732190340,"startTime":"0","endTime":"0","summary":"Next-generation domain controller offers full-cabin electronics from a single Garmin control module. OLATHE, Kan., Nov. 21, 2024 /PRNewswire/ -- Garmin  today announced that its Unified Cabin domain controller solution has been recognized as a Consumer Electronics Show  2025 Innovation Award Honoree in the in-vehicle entertainment category.First revealed at CES 2023, Garmin Unified Cabin is a scalable portfolio of automotive OEM technologies and design innovations that allow automakers to provide a personalized infotainment experience. With immersive theming and AI-driven customization, Unified Cabin remembers each passenger's preferences and picks up movies and videos where they left off while intuitively adjusting audio levels and seat settings. Fully integrated into Garmin's domain controller with a single control module, Unified Cabin is built on the Android Automotive Operating System to support centralized control of the vehicle's systems.About Garmin International, Inc. Garmin I","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wtJNfnyVmKN86hQ4W_0eDw--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2153975b71e56150c0aef1d9e98de2a6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wtJNfnyVmKN86hQ4W_0eDw--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/2153975b71e56150c0aef1d9e98de2a6"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/garmin-unified-cabin-automotive-oem-115900586.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/garmin-unified-cabin-automotive-oem-115900586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GRMN","BK4078","CTA","BK4585","BK4533","BK4588"],"gpt_icon":0},{"id":"2484419752","title":"Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2484419752","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484419752?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:00","pubTimestamp":1732104000,"startTime":"0","endTime":"0","summary":"- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro gene therapy development candidate nomina","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/20/2984297/36461/en/Voyager-Selects-Tau-Silencing-Gene-Therapy-Development-Candidate-for-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","CTA","CNS"],"gpt_icon":0},{"id":"2484919982","title":"Man Group's trend tracking fund is having one of its worst years ever","url":"https://stock-news.laohu8.com/highlight/detail?id=2484919982","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484919982?lang=en_us&edition=fundamental","pubTime":"2024-11-19 18:45","pubTimestamp":1732013100,"startTime":"0","endTime":"0","summary":"Stock markets have surged this year in an historic rally, but that doesn't mean everyone has managed to make outsize gains in 2024 - particularly in the volatile world of trend tracking hedge funds.Man Group, the world's largest publicly listed hedge fund, has instead seen one of its leading trend tracking funds post negative gains in the year-to-date that have put it on track for one of the worst years in its history.Man Group's AHL Trend Alternative fund, which manages more than $783 million worth of assets, posted -7.26% returns in October and is currently down 12.77% in the year-to-date, according to figures from data provider Kpler.Speaking to MarketWatch, Harald Berlinicke, a partner at fund manager Sarnia Asset Management, explained that: \"Trend followers got hit by the sharp turnaround in U.S. and European bond markets during October.\". Speaking to MarketWatch, Andrew Beer, managing member of DBi, which creates exchange traded funds  that replicate hedge fund strategies, explai","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2483719143","title":"Hydrific Named as CES Innovation Awards 2025 Honoree","url":"https://stock-news.laohu8.com/highlight/detail?id=2483719143","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483719143?lang=en_us&edition=fundamental","pubTime":"2024-11-15 21:48","pubTimestamp":1731678480,"startTime":"0","endTime":"0","summary":"Hydrific has been named a CES Innovation Awards 2025 Honoree for its smart home water sensor, Droplet.The awards celebrate outstanding design and engineering in consumer technology products.The 2025 awards program received a record number of submissions – over 3400 and marks the third award honoring Droplet this year.NEW YORK, Nov. 15, 2024 /PRNewswire/ -- Hydrific, part of LIXIL, has been named a CES Innovation Awards 2025 Honoree for its smart home water sensor, Droplet. The announcement comes ahead of CES 2025, the world's most powerful technology event, where Hydrific will showcase Droplet for the first time in Eureka Park. It also marks the third award that Droplet has received this year.About LIXILLIXIL  makes pioneering water and housing products that solve everyday, real-life challenges, making better homes a reality for everyone, everywhere. Drawing on our Japanese heritage, we create world-leading technology and innovate to make high-quality products that transform homes. But","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/A57gezRRtBbWL24yMEjFCQ--~B/aD0xNTQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/89005b6b2fddf9700c39b95b4d6105d1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/A57gezRRtBbWL24yMEjFCQ--~B/aD0xNTQ7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/89005b6b2fddf9700c39b95b4d6105d1"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hydrific-named-ces-innovation-awards-134800835.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hydrific-named-ces-innovation-awards-134800835.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["JSGCF","CTA","BK4086","JSGRY"],"gpt_icon":0},{"id":"2483322581","title":"Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B","url":"https://stock-news.laohu8.com/highlight/detail?id=2483322581","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483322581?lang=en_us&edition=fundamental","pubTime":"2024-11-15 20:00","pubTimestamp":1731672000,"startTime":"0","endTime":"0","summary":"– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study –。– Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and efficacy measured by durable reduction of key viral biomarkers –。– Global study recruiting patients following clearance of first clinical trial application , with additional CTAs pending approval; U.S. investigational new drug  anticipated in 2025 –。\"Our preclinical results reflect the robust data package submitted to regulators in support of our global Phase 1 trial and underscore our conviction in PBGENE-HBV, which has so far demonstrated compelling safety and selectivity, highly efficient editing, and confirmation of its mechanism to eliminate cccDNA and viral DNA integrated into hepatocytes,\" said Murray Abramson, M.D., M.P.H., Head of Clinical Development, Precision BioSciences. \"Importantly, the ELIMINATE-B stud","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mcMMK.RfJGNKdNFVBBesWQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/29ea110260d3a37f8202c23e968d9f26","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mcMMK.RfJGNKdNFVBBesWQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/29ea110260d3a37f8202c23e968d9f26"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/precision-biosciences-highlights-preclinical-data-120000262.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTA","DTIL","BK4139"],"gpt_icon":0},{"id":"2483337470","title":"Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337470","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337470?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"NEW YORK and MELBOURNE, Australia, Nov.  14, 2024  (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981582/0/en/Incannex-Healthcare-Inc-Reports-Fiscal-First-Quarter-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4510","HCSG","BK4167","BK4563","IH","AHI","BK4137","RA","BK4085","CTA","BK4097"],"gpt_icon":0},{"id":"2483713876","title":"Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483713876","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483713876?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:00","pubTimestamp":1731585600,"startTime":"0","endTime":"0","summary":"– Clinical data from the RESET-Myositis and RESET-SLE trials, along with initial clinical data from the RESET-SSc trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 –。– 16 patients enrolled with 10 patientsdosed as of November 12 across the RESET clinical development program; 40 U.S. clinical sites actively recruiting patients –。– Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 –。– Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International –。PHILADELPHIA, Nov. 14, 2024  -- Cabaletta Bio, Inc. , a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2024, and pro","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XkuCJ9SyHKT3sY6mHDS9Wg--~B/aD0xMDU7dz03OTQ7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/5ceb8c6cf4513e768545b54293484b77"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cabaletta-bio-reports-third-quarter-120000573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","BK4139","CHRO","ACR","CABA","CTA","SLE","BK4110"],"gpt_icon":0},{"id":"2483839249","title":"PHAXIAM Reports Third-Quarter 2024 Financial Information","url":"https://stock-news.laohu8.com/highlight/detail?id=2483839249","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483839249?lang=en_us&edition=fundamental","pubTime":"2024-11-14 00:45","pubTimestamp":1731516300,"startTime":"0","endTime":"0","summary":"Cash and cash equivalents of 5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/13/2980518/0/en/PHAXIAM-Reports-Third-Quarter-2024-Financial-Information.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","CTA","III"],"gpt_icon":0},{"id":"2483052542","title":"Press Release: Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483052542","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483052542?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025. Anticipate reporting data from REVEAL-1 open-label cohort beginning in Q4 2024. Topline data from REVITALIZE-1 pivotal study expected in mid-2025. Company presented compelling weight maintenance data from both Revita and Rejuva platforms at ObesityWeek 2024. BURLINGTON, Mass, Nov. 12, 2024  -- Fractyl Health, Inc.  , a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes , today reported its third quarter 2024 financial results and provided business updates.and lowering of blood sugar from Rejuva RJVA-001 for 13-weeks --","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GUTS","CTA","BK4022","R","BK4082","BK4232"],"gpt_icon":0},{"id":"2483054022","title":"Voyager Reports Third Quarter 2024 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483054022","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483054022?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:01","pubTimestamp":1731445260,"startTime":"0","endTime":"0","summary":"- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical data es","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979632/36461/en/Voyager-Reports-Third-Quarter-2024-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA"],"gpt_icon":0},{"id":"2483805258","title":"Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483805258","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483805258?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:00","pubTimestamp":1731445200,"startTime":"0","endTime":"0","summary":"-- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024 and remains on track to file IND and/or CTA in 1H 2026 --. -- Announced strategic research collaboration and license agreement with Bristol Myers Squibb; received $110 million upfront, with potential for more than $3.5 billion in milestone payments --. Dr. Gottesdiener continued, “Also in recent months, we announced our decision to strategically prioritize a set of high value programs, each with a clear path to value inflection and the potential to unlock multiple follow-on opportunities. This includes our wholly owned efforts in CGD and Wilson’s Disease, as well as our efforts in cell therapy and cystic fibrosis, which we are advancing with support from Bristol Myers Squibb and the Cystic Fibrosis Foundation, respectively. We believe partnerships like these will continue to play a critical role as we build P","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/oPDNSXBzIFbD2e.XWB7MDA--~B/aD0zNzUwO3c9MTEyNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/300f275153cd1bd628bbd71855c8c15c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/oPDNSXBzIFbD2e.XWB7MDA--~B/aD0zNzUwO3c9MTEyNDM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/300f275153cd1bd628bbd71855c8c15c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/prime-medicine-reports-third-quarter-210000883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0321505439.SGD","BK4093","IE00B2B36J28.USD","CTA","LU2133065610.SGD","LU0306807586.USD","LU1032466523.USD","BK4588","BK4559","LU1093756168.USD","LU0225284248.USD","LU0114720955.EUR","LU1670710588.SGD","LU0225771236.USD","BMY","LU0061475181.USD","LU0882574055.USD","LU1430594728.SGD","LU2242652126.USD","IE0002141913.USD","LU1670711040.USD","LU0237698245.USD","LU1291159041.SGD","BK4581","IE00BFTCPJ56.SGD","BK4534","IE0009355771.USD","LU1571399168.USD","LU1261432733.SGD","IE00BSNM7G36.USD","LU1670710661.SGD","LU1989771016.USD","BK4532","LU0321505868.SGD","BK4007","PRME","LU1074936037.SGD","CF","LU0456855351.SGD","LU0868494617.USD","LU1093756325.SGD","LU2125154935.USD","LU2360032135.SGD","IE00BJJMRZ35.SGD","LU1718418525.SGD","LU2125154778.USD","BK4585","LU2242646821.SGD","IE00BJT1NW94.SGD","LU0985481810.HKD"],"gpt_icon":0},{"id":"2482017709","title":"Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482017709","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482017709?lang=en_us&edition=fundamental","pubTime":"2024-11-12 21:00","pubTimestamp":1731416400,"startTime":"0","endTime":"0","summary":"In October, Ocuphire Pharma acquired Opus Genetics, creating a leading, clinical-stage company focused on the development of gene therapy treatments for rare inherited retinal diseases (IRDs) The pro ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979129/0/en/Opus-Genetics-Announces-Financial-Results-for-Third-Quarter-2024-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTA","LCA","SPA"],"gpt_icon":0},{"id":"2482470695","title":"CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482470695","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482470695?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:20","pubTimestamp":1731414000,"startTime":"0","endTime":"0","summary":"Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter. 400 million upfront payment from restructured GSK collaboration reflected in financials, cash position increased to 551 million; expected cash runway re-affirmed into 2028. CVGBM Phase 1 glioblastoma study showed 77% of patients with antigen-specific T-cell responses; data presented at ESMO, SITC and SNO. New off-the-shelf program for squamous non-small cell lung cancer started, expected to enter Phase 1 in H2 2025. New preclinical prophylactic vaccine program for urinary tract infections initiated, supported by positive preclinical data versus protein-based vaccines. Positive Phase 2 data from seasonal influenza program licensed to GSK demonstrated strong immune responses against challenging influenza B as well as A strains; program progressing to Phase 3, which will be associated with significant milestone payment. Corporate redesign on track with 30% workforce reduction, expected to yield signi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bx7cdeRNxEwazNcDWucEIw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/a0ea1b5efd3fe31259aaba2e79e18980"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/curevac-announces-financial-results-third-122000623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CVAC","BK4080","BK4548","SITC","BK4139","BK4551","BK4231","CTA","CMO"],"gpt_icon":1}],"pageSize":16,"totalPage":4,"pageCount":3,"totalSize":62}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CTA\",params:#limit:5,,,undefined,":[{"date":"2025-03-26","symbol":"CTA","amount":0.12,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-31","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-31"},{"date":"2024-12-23","symbol":"CTA","amount":0.73816,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-31"},{"date":"2024-09-25","symbol":"CTA","amount":0.3,"announcedDate":"2024-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-09-25","defaultRemindTime":1727271000000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-09-30","payableDate":"2024-09-25","currency":"USD","dateTimestamp":1727236800000,"payDate":"2024-09-30"},{"date":"2024-06-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-28","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-06-28"},{"date":"2024-03-25","symbol":"CTA","amount":0.15,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-26","defaultRemindTime":1711373400000,"name":"SIMPLIFY MANAGED FUTURES STRATEGY ETF","recordDate":"2024-03-28","payableDate":"2024-03-26","currency":"USD","dateTimestamp":1711339200000,"payDate":"2024-03-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CTA\",market:\"US\",,,undefined,":[{"executeDate":"2022-08-26","recordDate":"2022-08-29","paymentDate":"2022-08-31","value":0.15,"currency":"USD"},{"executeDate":"2022-09-27","recordDate":"2022-09-28","paymentDate":"2022-09-30","value":0.15,"currency":"USD"},{"executeDate":"2022-10-26","recordDate":"2022-10-27","paymentDate":"2022-10-31","value":0.15,"currency":"USD"},{"executeDate":"2022-11-25","recordDate":"2022-11-28","paymentDate":"2022-11-30","value":0.15,"currency":"USD"},{"executeDate":"2022-12-27","recordDate":"2022-12-28","paymentDate":"2022-12-30","value":1.11096,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CTA\",market:\"US\",delay:false,,,undefined,":{}}}